Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection

References

• Logroscino G, Traynor BJ, Hardiman O, et al. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry. 2008 Jan;79(1):6–11.
   PubMed Web of Science ®Google Scholar
• Ingre C, Roos PM, Piehl F, et al. Risk factors for amyotrophic lateral sclerosis. Clin Epidemiol. 2015;7:181–193.
   PubMed Web of Science ®Google Scholar
• Bakkar N, Boehringer A, Bowser R. Use of biomarkers in ALS drug development and clinical trials. Brain Res. 2015 May;1607(1607):94–107.
   PubMed Web of Science ®Google Scholar
• Pradat P-F, Kabashi E, Desnuelle C. Deciphering spreading mechanisms in amyotrophic lateral sclerosis: clinical evidence and potential molecular processes. Curr Opin Neurol. 2015 Oct;28(5):455–461.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994 Mar 3; 330(9):585–591.
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996 May 25; 347(9013):1425–1431.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology. 2006 Mar 14;66(5):647–653.
   PubMed Web of Science ®Google Scholar
• Logroscino G, Traynor BJ, Hardiman O, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010 Apr;81(4):385–390.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013 Nov;9(11):617–628.
   PubMed Web of Science ®Google Scholar
• Alonso A, Logroscino G, Jick SS, et al. Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. ‎Eur J Neurol: Official J Eur Fed Neuroll Soc. 2009 Jun;16(6):745–751.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293–299.
   PubMed Web of Science ®Google Scholar
• Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009 Oct 13;73(15):1218–1226.
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Alexander M, Corr B, et al. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000. J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1258–1261.
   PubMed Web of Science ®Google Scholar
• Rowland LP. The quality of neurological care, 1997. Arch Neurol. 1997 Nov;54(11):1327–1328.
   PubMedGoogle Scholar
• Andersen PM, Nilsson P, Forsgren L, et al. CuZn-superoxide dismutase, extracellular superoxide dismutase, and glutathione peroxidase in blood from individuals homozygous for Asp90Ala CuZu-superoxide dismutase mutation. J Neurochem. 1998 Feb;70(2):715–720.
   PubMed Web of Science ®Google Scholar
• Andersen PM. The genetics of amyotrophic lateral sclerosis (ALS). Suppl Clin Neurophysiol. 2004;57:211–227.
   PubMedGoogle Scholar
• Bruijn LI, Houseweart MK, Kato S, et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science. 1998 Sep 18;281(5384):1851–1854.
   PubMed Web of Science ®Google Scholar
• Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011 Oct 20;72(2):257–268.
   PubMed Web of Science ®Google Scholar
• DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011 Oct 20;72(2):245–256.
   PubMed Web of Science ®Google Scholar
• Gijselinck I, Van Langenhove T, van der Zee J, et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol. 2012 Jan;11(1):54–65.
   PubMed Web of Science ®Google Scholar
• Belzil VV, Bauer PO, Prudencio M, et al. Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathol. 2013 Dec;126(6):895–905.
   PubMed Web of Science ®Google Scholar
• Yokoseki A, Shiga A, Tan CF, et al. TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann Neurol. 2008 Apr;63(4):538–542.
   PubMed Web of Science ®Google Scholar
• Rutherford NJ, Zhang YJ, Baker M, et al. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet. 2008;4(9):e1000193.
   PubMed Web of Science ®Google Scholar
• Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006 Oct 6;314(5796):130–133.
   PubMed Web of Science ®Google Scholar
• Marangi G, Traynor BJ. Genetic causes of amyotrophic lateral sclerosis: new genetic analysis methodologies entailing new opportunities and challenges. Brain Res. 2015 May;1607(1607):75–93.
   PubMed Web of Science ®Google Scholar
• Lattante S, Ciura S, Rouleau GA, et al. Defining the genetic connection linking amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD). Trends Genet. 2015 May;31(5):263–273.
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014 Nov;13(11):1127–1138.
   PubMed Web of Science ®Google Scholar
• Vucic S, Rothstein JD, Kiernan MC. Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends Neurosci. 2014 Aug;37(8):433–442.
   PubMed Web of Science ®Google Scholar
• Babin PJ, Goizet C, Raldua D. Zebrafish models of human motor neuron diseases: advantages and limitations. Prog Neurobiol. 2014 Jul;118:36–58.
   PubMed Web of Science ®Google Scholar
• Tsao W, Jeong YH, Lin S, et al. Rodent models of TDP-43: recent advances. Brain Research. 2012 Jun 26;1462:26–39.
   PubMed Web of Science ®Google Scholar
• Lanson NA Jr., Pandey UB. FUS-related proteinopathies: lessons from animal models. Brain Res. 2012 Jun;26(1462):44–60.
   Web of Science ®Google Scholar
• Perrin S. Preclinical research: make mouse studies work. Nature. 2014 Mar 27;507(7493):423–425.
   PubMed Web of Science ®Google Scholar
• Hedges EC, Mehler VJ, Nishimura AL. The use of stem cells to model amyotrophic lateral sclerosis and frontotemporal dementia: from basic research to regenerative medicine. Stem Cells Int. 2016;2016:9279516.
   PubMed Web of Science ®Google Scholar
• Nishimura AL, Shum C, Scotter EL, et al. Allele-specific knockdown of ALS-associated mutant TDP-43 in neural stem cells derived from induced pluripotent stem cells. PLoS One. 2014;9(3):e91269.
   PubMed Web of Science ®Google Scholar
• Wray S, Self M, Lewis PA, et al. Creation of an open-access, mutation-defined fibroblast resource for neurological disease research. PLoS One. 2012;7(8):e43099.
   Google Scholar
• Simon NG, Turner MR, Vucic S, et al. Quantifying disease progression in amyotrophic lateral sclerosis. Ann Neurol. 2014 Nov;76(5):643–657.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999 Oct 31;169(1–2):13–21.
   PubMed Web of Science ®Google Scholar
• Kimura F, Fujimura C, Ishida S, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006 Jan 24;66(2):265–267.
   PubMed Web of Science ®Google Scholar
• Berry JD, Miller R, Moore DH, et al. The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Jan;14(3):162–168.
   PubMed Web of Science ®Google Scholar
• Rudnicki SA, Berry JD, Ingersoll E, et al. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Jan;14(1):44–51.
   PubMed Web of Science ®Google Scholar
• Goonetilleke A, De Belleroche J, Guiloff RJ. Motor neurone disease. Essays Biochem. 1994;28:27–45.
   PubMed Web of Science ®Google Scholar
• Andres PL, Skerry LM, Thornell B, et al. A comparison of three measures of disease progression in ALS. J Neurol Sci. 1996 Aug;139(Suppl):64–-70.
   PubMed Web of Science ®Google Scholar
• Andres PL, Hedlund W, Finison L, et al. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology. 1986 Jul;36(7):937–941.
   PubMed Web of Science ®Google Scholar
• Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2006 Mar;77(3):390–392.
   PubMed Web of Science ®Google Scholar
• Baumann F, Rose SE, Nicholson GA, et al. Biomarkers of disease in a case of familial lower motor neuron ALS. Amyotroph Lateral Scler. 2010 Oct;11(5):486–489.
   PubMed Web of Science ®Google Scholar
• Fitting JW, Paillex R, Hirt L, et al. Sniff nasal pressure: a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis. Ann Neurol. 1999 Dec;46(6):887–893.
   PubMed Web of Science ®Google Scholar
• Ludolph AC, Bendotti C, Blaugrund E, et al. Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph Lateral Scler. 2010;11(1–2):38–45.
   PubMed Web of Science ®Google Scholar
• Schoenfeld DA, Cudkowicz M. Design of phase II ALS clinical trials. Amyotroph Lateral Scler. 2008;9(1):16–23.
   PubMed Web of Science ®Google Scholar
• Turner MR, Kiernan MC, Leigh PN, et al. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009 Jan;8(1):94–109.
   PubMed Web of Science ®Google Scholar
• Otto M, Bowser R, Turner M, et al. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler. 2012 Jan;13(1):1–10.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Meininger V. How can we improve clinical trials in amyotrophic lateral sclerosis? Nat Rev Neurol. 2011 Nov;7(11):650–654.
   PubMed Web of Science ®Google Scholar
• Menke RA, Gray E, Lu CH, et al. CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol. 2015 Jul;2(7):748–755.
   PubMed Web of Science ®Google Scholar
• Chen H, Qian K, Du Z, et al. Modeling ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor neurons. Cell Stem Cell. 2014 Jun 5;14(6):796–809.
   PubMed Web of Science ®Google Scholar
• Lu CH, Petzold A, Kalmar B, et al. Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALS. PLoS One. 2012;7(7):e40998.
   Google Scholar
• Ganesalingam J, An J, Shaw CE, et al. Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem. 2011 May;117(3):528–537.
   PubMed Web of Science ®Google Scholar
• Boylan K, Yang C, Crook J, et al. Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J Neurochem. 2009 Dec;111(5):1182–1191.
   PubMed Web of Science ®Google Scholar
• Reijn TS, Abdo WF, Schelhaas HJ, et al. CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol. 2009 Apr;256(4):615–619.
   PubMed Web of Science ®Google Scholar
• Zhuo JM, Wang H, Pratico D. Is hyperhomocysteinemia an Alzheimer’s disease (AD) risk factor, an AD marker, or neither? Trends Pharmacol Sci. 2011 Sep;32(9):562–571.
   PubMed Web of Science ®Google Scholar
• Steinacker P, Hendrich C, Sperfeld AD, et al. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol. 2008 Nov;65(11):1481–1487.
   PubMedGoogle Scholar
• Sjogren M, Gustafson L, Wikkelso C, et al. Frontotemporal dementia can be distinguished from Alzheimer’s disease and subcortical white matter dementia by an anterior-to-posterior rCBF-SPET ratio. Dement Geriatr Cogn Disord. 2000 Sep–Oct;11(5):275–285.
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Petzold A, Sussmuth SD, et al. Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes. Mov Disord. 2006 Dec;21(12):2224–2227.
   PubMed Web of Science ®Google Scholar
• Ganesalingam J, Bowser R. The application of biomarkers in clinical trials for motor neuron disease. Biomark Med. 2010 Apr;4(2):281–297.
   PubMed Web of Science ®Google Scholar
• Shevchenko G, Konzer A, Musunuri S, et al. Neuroproteomics tools in clinical practice. Biochim Biophys Acta. 2015 Jul;1854(7):705–717.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Mizuno Y, Fujita Y. Bunina bodies in amyotrophic lateral sclerosis. Neuropathology. 2008 Apr;28(2):109–115.
   PubMed Web of Science ®Google Scholar
• Mendonca DM, Pizzati L, Mostacada K, et al. Neuroproteomics: an insight into ALS. Neurol Res. 2012 Dec;34(10):937–943.
   PubMed Web of Science ®Google Scholar
• Zecca L, Youdim MB, Riederer P, et al. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004 Nov;5(11):863–873.
   PubMed Web of Science ®Google Scholar
• Von Neuhoff N, Oumeraci T, Wolf T, et al. Monitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinic. PLoS One. 2012;7(9):e44401.
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Lehmensiek V, Mogel H, et al. Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS). Neurosci Lett. 2010 Jan 1;468(1):23–27.
   PubMed Web of Science ®Google Scholar
• Ryberg H, Bowser R. Protein biomarkers for amyotrophic lateral sclerosis. Expert Rev Proteomics. 2008 Apr;5(2):249–262.
   PubMed Web of Science ®Google Scholar
• Lerman BJ, Hoffman EP, Sutherland ML, et al. Deletion of galectin-3 exacerbates microglial activation and accelerates disease progression and demise in a SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Brain Behav. 2012 Sep;2(5):563–575.
   PubMed Web of Science ®Google Scholar
• Paez-Colasante X, Figueroa-Romero C, Sakowski SA, et al. Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era. Nat Rev Neurol. 2015 May;11(5):266–279.
   PubMed Web of Science ®Google Scholar
• Trushina E, Mielke MM. Recent advances in the application of metabolomics to Alzheimer’s Disease. Biochim Biophys Acta. 2013 Jun;1842(8):1232–1239.
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Beghi E, Palagano G, et al. Predictors of long survival in amyotrophic lateral sclerosis: a population-based study. J Neurol Sci. 2008 May 15;268(1–2):28–32.
   PubMed Web of Science ®Google Scholar
• Testa D, Lovati R, Ferrarini M, et al. Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Dec;5(4):208–212.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Nagaoka U, Nakayama Y, et al. Reduction rate of body mass index predicts prognosis for survival in amyotrophic lateral sclerosis: a multicenter study in Japan. Amyotroph Lateral Scler. 2012 Jun;13(4):363–366.
   PubMed Web of Science ®Google Scholar
• Scotton WJ, Scott KM, Moore DH, et al. Prognostic categories for amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012 Oct;13(6):502–508.
   PubMed Web of Science ®Google Scholar
• Millul A, Beghi E, Logroscino G, et al. Survival of patients with amyotrophic lateral sclerosis in a population-based registry. Neuroepidemiology. 2005;25(3):114–119.
   PubMed Web of Science ®Google Scholar
• Magnus T, Beck M, Giess R, et al. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve. 2002 May;25(5):709–714.
   PubMed Web of Science ®Google Scholar
• Louwerse ES, Visser CE, Bossuyt PM, et al. Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. The Netherlands ALS Consortium. J Neurol Sci. 1997 Oct;152(Suppl 1):S10–7.
   PubMed Web of Science ®Google Scholar
• Kollewe K, Mauss U, Krampfl K, et al. ALSFRS-R score and its ratio: a useful predictor for ALS-progression. J Neurol Sci. 2008 Dec 15;275(1–2):69–73.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Salachas F, Lacomblez L, et al. Predicting survival of patients with amyotrophic lateral sclerosis at presentation: a 15-year experience. Neurodegener Dis. 2013;12(2):81–90.
   PubMed Web of Science ®Google Scholar
• Del Aguila MA, Longstreth WT Jr., McGuire V, et al. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology. 2003 Mar 11;60(5):813–819.
   PubMed Web of Science ®Google Scholar
• Czaplinski A, Yen AA, Appel SH. Amyotrophic lateral sclerosis: early predictors of prolonged survival. J Neurol. 2006 Nov;253(11):1428–1436.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Salachas F, Lacomblez L, et al. Predicting survival of patients with amyotrophic lateral sclerosis at presentation: a 15-Year experience. Neurodegener Dis. 2012 Aug;12(2):81–90.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Miller RG, Moore DH. Alsfrs-R. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;Suppl 5(1):90–93.
   Web of Science ®Google Scholar
• Gordon PH, Corcia P, Lacomblez L, et al. Defining survival as an outcome measure in amyotrophic lateral sclerosis. Arch Neurol. 2009 Jun;66(6):758–761.
   PubMedGoogle Scholar
• Gordon PH, Cheung YK. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006 Oct 10;67(7):1314–1315. author reply 14-5.
   PubMed Web of Science ®Google Scholar
• Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995 Jun;118(Pt 3):707–719.
   PubMed Web of Science ®Google Scholar
• Bede P, Hardiman O. Lessons of ALS imaging: pitfalls and future directions - A critical review. Neuroimage Clin. 2014;4:436–443.
   PubMed Web of Science ®Google Scholar
• Pradat PF, El Mendili MM. Neuroimaging to investigate multisystem involvement and provide biomarkers in amyotrophic lateral sclerosis. Biomed Res Int. 2014;2014:467560.
   PubMed Web of Science ®Google Scholar
• Blasco H, Nadal-Desbarats L, Pradat PF, et al. Untargeted 1H-NMR metabolomics in CSF: toward a diagnostic biomarker for motor neuron disease. Neurology. 2014 Apr 1;82(13):1167–1174.
   PubMed Web of Science ®Google Scholar
• Hardiman O. Symptomatic treatment of respiratory and nutritional failure in amyotrophic lateral sclerosis. J Neurol. 2000 Apr;247(4):245–251.
   PubMed Web of Science ®Google Scholar
• Hardiman O. Management of respiratory symptoms in ALS. J Neurol. 2011 Mar;258(3):359–365.
   PubMed Web of Science ®Google Scholar
• O’Doherty LJ, Hickey A, Hardiman O. Measuring life quality, physical function and psychological well-being in neurological illness. Amyotroph Lateral Scler. 2010 Oct;11(5):461–468.
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, et al. Long-term safety of riluzole in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002 Mar;3(1):23–29.
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Bruijn L, Conwit R, et al. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology. 2006 Jul 11;67(1):20–27.
   PubMed Web of Science ®Google Scholar
• Meininger V, Pradat PF, Corse A, et al. Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial. PLoS One. 2014;9(5):e97803.
   PubMedGoogle Scholar
• Hey SP, Kimmelman J. The risk-escalation model: a principled design strategy for early-phase trials. Kennedy Inst Ethics J. 2014 Jun;24(2):121–139.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Cheng B, Montes J, et al. Outcome measures for early phase clinical trials. Amyotroph Lateral Scler. 2007 Oct;8(5):270–273.
   PubMed Web of Science ®Google Scholar
• Nanasi PP, Jednakovits A Multilateral in vivo and in vitro protective effects of the novel heat shock protein coinducer, bimoclomol: results of preclinical studies. Cardiovasc Drug Rev. Summer 2001;19(2):133–151.
   PubMed Web of Science ®Google Scholar
• Welch WJ. The role of heat-shock proteins as molecular chaperones. Curr Opin Cell Biol. 1991 Dec;3(6):1033–1038.
   PubMed Web of Science ®Google Scholar
• Hargitai J, Lewis H, Boros I, et al. Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1. Biochem Biophys Res Commun. 2003 Aug 1;307(3):689–695.
   PubMed Web of Science ®Google Scholar
• Kieran D, Kalmar B, Dick JR, et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med. 2004 Apr;10(4):402–405.
   PubMed Web of Science ®Google Scholar
• Kalmar B, Novoselov S, Gray A, et al. Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS. J Neurochem. 2008 Oct;107(2):339–350.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Shefner JM, Simpson E, et al. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle Nerve. 2008 Jul;38(1):837–844.
   PubMed Web of Science ®Google Scholar
• Hemendinger RA, Armstrong EJ 3rd, Brooks BR. Methyl Vitamin B12 but not methylfolate rescues a motor neuron-like cell line from homocysteine-mediated cell death. Toxicol Appl Pharmacol. 2011 Mar 15;251(3):217–225.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Iwasaki Y, Kaji R. Neuroprotective effect of ultra-high dose methylcobalamin in wobbler mouse model of amyotrophic lateral sclerosis. J Neurol Sci. 2015 Jul 15;354(1–2):70–74.
   PubMed Web of Science ®Google Scholar
• Pratt AJ, Getzoff ED, Perry JJ. Amyotrophic lateral sclerosis: update and new developments. Degener Neurol Neuromuscul Dis. 2012 Feb;2012(2):1–14.
   PubMedGoogle Scholar
• Izumi Y, Kaji R. Clinical trials of ultra-high-dose methylcobalamin in ALS. Brain Nerve. 2007 Oct;59(10):1141–1147.
   PubMedGoogle Scholar
• Watanabe T, Kaji R, Oka N, et al. Ultra-high dose methylcobalamin promotes nerve regeneration in experimental acrylamide neuropathy. J Neurol Sci. 1994 Apr;122(2):140–143.
   PubMed Web of Science ®Google Scholar
• Kaji R, Kodama M, Imamura A, et al. Effect of ultrahigh-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: a double-blind controlled study. Muscle Nerve. 1998 Dec;21(12):1775–1778.
   PubMed Web of Science ®Google Scholar
• Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist–a review of preclinical data. Neuropharmacology. 1999 Jun;38(6):735–767.
   PubMed Web of Science ®Google Scholar
• Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004 Jan 21;291(3):317–324.
   PubMed Web of Science ®Google Scholar
• Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009 Jun;80(6):600–607.
   PubMed Web of Science ®Google Scholar
• van Dyck CH, Tariot PN, Meyers B, et al. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2007 Apr-Jun;21(2):136–143.
   PubMed Web of Science ®Google Scholar
• Reisberg B, Doody R, Stoffler A, et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol. 2006 Jan;63(1):49–54.
   PubMedGoogle Scholar
• Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009 Jul;8(7):613–618.
   PubMed Web of Science ®Google Scholar
• Wilcock G, Mobius HJ, Stoffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002 Nov;17(6):297–305.
   PubMed Web of Science ®Google Scholar
• Orgogozo JM, Rigaud AS, Stoffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002 Jul;33(7):1834–1839.
   PubMed Web of Science ®Google Scholar
• Johnson JW, Glasgow NG, Povysheva NV. Recent insights into the mode of action of memantine and ketamine. Curr Opin Pharmacol. 2015 Feb;20:54–63.
   PubMed Web of Science ®Google Scholar
• Kornhuber J, Weller M. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry. 1997 Jan 15;41(2):135–144.
   PubMed Web of Science ®Google Scholar
• Kornhuber J, Quack G. Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett. 1995 Aug 4;195(2):137–139.
   PubMed Web of Science ®Google Scholar
• Bormann J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol. 1989 Aug 3;166(3):591–592.
   PubMed Web of Science ®Google Scholar
• Parsons CG, Gruner R, Rozental J, et al. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology. 1993 Dec;32(12):1337–1350.
   PubMed Web of Science ®Google Scholar
• Chen HS, Lipton SA. The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem. 2006 Jun;97(6):1611–1626.
   PubMed Web of Science ®Google Scholar
• Van Den Bosch L, Van Damme P, Bogaert E, et al. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta. 2006 Nov–Dec;1762(11–12):1068–1082.
   PubMed Web of Science ®Google Scholar
• Blasco H, Mavel S, Corcia P, et al. The glutamate hypothesis in ALS: pathophysiology and drug development. Curr Med Chem. 2014;21(31):3551–3575.
   PubMed Web of Science ®Google Scholar
• Sonkusare SK, Kaul CL, Ramarao P. Dementia of Alzheimer’s disease and other neurodegenerative disorders–memantine, a new hope. Pharmacol Res. 2005 Jan;51(1):1–17.
   PubMed Web of Science ®Google Scholar
• Yanez M, Matias-Guiu J, Arranz-Tagarro JA, et al. The neuroprotection exerted by memantine, minocycline and lithium, against neurotoxicity of CSF from patients with amyotrophic lateral sclerosis, is antagonized by riluzole. Neurodegener Dis. 2014;13(2–3):171–179.
   PubMed Web of Science ®Google Scholar
• Wenk GL, Zajaczkowski W, Danysz W. Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B. Behav Brain Res. 1997 Feb;83(1–2):129–133.
   PubMed Web of Science ®Google Scholar
• Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, et al. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1–40). Brain Res. 2002 Dec 20;958(1):210–221.
   PubMed Web of Science ®Google Scholar
• Wang R, Zhang D. Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Eur J Neurosci. 2005 Nov;22(9):2376–2380.
   PubMed Web of Science ®Google Scholar
• Joo IS, Hwang DH, Seok JI, et al. Oral administration of memantine prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Clin Neurol. 2007 Dec;3(4):181–186.
   PubMed Web of Science ®Google Scholar
• De Carvalho M, Pinto S, Costa J, et al. A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010 Oct;11(5):456–460.
   PubMed Web of Science ®Google Scholar
• Levine TD, Bowser R, Hank N, et al. A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers. Amyotroph Lateral Scler. 2010 Dec;11(6):514–519.
   PubMed Web of Science ®Google Scholar
• Takahashi R. Edaravone in ALS. Exp Neurol. 2009 Jun;217(2):235–236.
   PubMed Web of Science ®Google Scholar
• Ito H, Wate R, Zhang J, et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol. 2008 Oct;213(2):448–455.
   PubMed Web of Science ®Google Scholar
• Aoki M, Warita H, Mizuno H, et al. Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger. Brain Res. 2011 Mar 25;1382:321–325.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Iwasaki Y. Edaravone, a free radical scavenger, delayed symptomatic and pathological progression of motor neuron disease in the Wobbler Mouse. PLoS One. 2015;10(10):e0140316.
   PubMed Web of Science ®Google Scholar
• Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler. 2006 Dec;7(4):241–245.
   PubMed Web of Science ®Google Scholar
• Abe K, Itoyama Y, Sobue G, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7–8):610–617.
   PubMed Web of Science ®Google Scholar
• Yang YM, Gupta SK, Kim KJ, et al. A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell. 2013 Jun 6;12(6):713–726.
   PubMed Web of Science ®Google Scholar
• Bordet T, Buisson B, Michaud M, et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther. 2007 Aug;322(2):709–720.
   PubMed Web of Science ®Google Scholar
• Sunyach C, Michaud M, Arnoux T, et al. Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model. Neuropharmacology. 2012 Jun;62(7):2346–2352.
   PubMed Web of Science ®Google Scholar
• Lenglet T, Lacomblez L, Abitbol JL, et al. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur J Neurol. 2014 Mar;21(3):529–536.
   PubMed Web of Science ®Google Scholar
• Solling C. Organ-protective and immunomodulatory effects of erythropoietin–an update on recent clinical trials. Basic Clin Pharmacol Toxicol. 2012 Feb;110(2):113–121.
   PubMed Web of Science ®Google Scholar
• Siren AL, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA. 2001 Mar 27;98(7):4044–4049.
   PubMed Web of Science ®Google Scholar
• Mennini T, De Paola M, Bigini P, et al. Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Mol Med. 2006 Jul–Aug;12(7–8):153–160.
   PubMed Web of Science ®Google Scholar
• Chung YH, Joo KM, Kim YS, et al. Enhanced expression of erythropoietin in the central nervous system of SOD1(G93A) transgenic mice. Brain Res. 2004 Aug 6;1016(2):272–280.
   PubMed Web of Science ®Google Scholar
• Grunfeld JF, Barhum Y, Blondheim N, et al. Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model. Exp Neurol. 2007 Mar;204(1):260–263.
   PubMed Web of Science ®Google Scholar
• Janik P, Kwiecinski H, Sokolowska B, et al. Erythropoietin concentration in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Neural Transm. 2010 Mar;117(3):343–347.
   PubMed Web of Science ®Google Scholar
• Lauria G, Dalla Bella E, Antonini G, et al. Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study. J Neurol Neurosurg Psychiatry. 2015 Aug;86(8):879–886.
   PubMed Web of Science ®Google Scholar
• Shefner JM, Watson ML, Meng L, et al. A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7–8):574–581.
   PubMed Web of Science ®Google Scholar
• Shefner JM, Wolff AA, Meng L. The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7–8):582–585.
   PubMed Web of Science ®Google Scholar
• Beal MF. Neuroprotective effects of creatine. Amino Acids. 2011 May;40(5):1305–1313.
   PubMed Web of Science ®Google Scholar
• Adhihetty PJ, Beal MF. Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Neuromolecular Med. 2008;10(4):275–290.
   PubMed Web of Science ®Google Scholar
• Pastula DM, Moore DH, Bedlack RS. Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2012;12:CD005225.
   Google Scholar
• Pastula DM, Moore DH, Bedlack RS. Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2010;6:CD005225.
   Google Scholar
• Folch J, Petrov D, Ettcheto M, et al. Masitinib for the treatment of mild to moderate Alzheimer’s disease. Expert Rev Neurother. 2015 Jun;15(6):587–596.
   PubMed Web of Science ®Google Scholar
• Calvo A, Moglia C, Balma M, et al. Involvement of immune response in the pathogenesis of amyotrophic lateral sclerosis: a therapeutic opportunity? CNS Neurol Disord Drug Targets. 2010 Jul;9(3):325–330.
   PubMed Web of Science ®Google Scholar
• Malaspina A, Puentes F, Amor S. Disease origin and progression in amyotrophic lateral sclerosis: an immunology perspective. Int Immunol. 2015 Mar;27(3):117–129.
   PubMed Web of Science ®Google Scholar
• Salvado M, Vargas V, Vidal M, et al. Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient. World J Gastroenterol. 2015 Sep 28;21(36):10475–10479.
   PubMed Web of Science ®Google Scholar
• Lunn JS, Sakowski SA, Feldman EL. Stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the future. Stem Cells. 2014 Jan;32(5):1099–1109.
   PubMed Web of Science ®Google Scholar
• Papadeas ST, Maragakis NJ. Advances in stem cell research for Amyotrophic Lateral Sclerosis. Curr Opin Biotechnol. 2009 Oct;20(5):545–551.
   PubMed Web of Science ®Google Scholar
• Glass JD, Boulis NM, Johe K, et al. Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells. 2012 Jun;30(6):1144–1151.
   PubMed Web of Science ®Google Scholar
• Feldman EL, Boulis NM, Hur J, et al. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol. 2014 Mar;75(3):363–373.
   PubMed Web of Science ®Google Scholar
• Minguell JJ, Allers C, Lasala GP. Mesenchymal stem cells and the treatment of conditions and diseases: the less glittering side of a conspicuous stem cell for basic research. Stem Cells Dev. 2013 Jan 15;22(2):193–203.
   PubMed Web of Science ®Google Scholar
• Urushitani M, Ezzi SA, Julien JP. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2007 Feb 13;104(7):2495–2500.
   PubMed Web of Science ®Google Scholar
• Gros-Louis F, Soucy G, Lariviere R, et al. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem. 2010 Jun;113(5):1188–1199.
   PubMed Web of Science ®Google Scholar
• Nieminen MS, Fruhwald S, Heunks LM, et al. Levosimendan: current data, clinical use and future development. Heart Lung Vessel. 2013;5(4):227–245.
   PubMedGoogle Scholar
• Nicholson KA, Cudkowicz ME, Berry JD. Clinical Trial Designs in Amyotrophic Lateral Sclerosis: does One Design Fit All? Neurotherapeutics. 2015 Apr;12(2):376–383.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Cheung YK, Levin B, et al. A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler. 2008 Aug;9(4):212–222.
   PubMed Web of Science ®Google Scholar
• Weckbach S, Losacco JT, Hahnhaussen J, et al. Challenging the dogma on inferiority of stainless steel implants for fracture fixation. An end of the controversy?. Unfallchirurg. 2012 Jan;115(1):75–79.
   PubMed Web of Science ®Google Scholar
• Gupta SK. Non-inferiority clinical trials: practical issues and current regulatory perspective. Indian J Pharmacol. 2011 Jul;43(4):371–374.
   PubMed Web of Science ®Google Scholar
• Bozik ME, Mitsumoto H, Brooks BR, et al. A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5–6):406–413.
   PubMed Web of Science ®Google Scholar
• Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013 May;12(5):435–442.
   PubMed Web of Science ®Google Scholar
• Fernandes SA, Douglas AG, Varela MA, et al. Oligonucleotide-Based Therapy for FTD/ALS Caused by the C9orf72 Repeat Expansion: a Perspective. J Nucleic Acids. 2013;2013:208245.
   PubMedGoogle Scholar
• Roche JC, Rojas-Garcia R, Scott KM, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012 Mar;135(Pt 3):847–852.
   PubMed Web of Science ®Google Scholar
• Balendra R, Jones A, Jivraj N, et al. Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3–4):279–284.
   PubMed Web of Science ®Google Scholar
• Balendra R, Jones A, Jivraj N, et al. Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):45–49.
   PubMed Web of Science ®Google Scholar
• Berry JD, Cudkowicz ME, Shefner JM. Predicting success: optimizing phase II ALS trials for the transition to phase III. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Mar;15(1–2):1–8.
   PubMed Web of Science ®Google Scholar
• Geldenhuys WJ. Van der Schyf CJ. Rationally designed multi-targeted agents against neurodegenerative diseases. Curr Med Chem. 2013;20(13):1662–1672.
   PubMed Web of Science ®Google Scholar
• Beghi E, Pupillo E, Bonito V, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Sep;14(5–6):397–405.
   PubMed Web of Science ®Google Scholar
• Kanouchi T, Ohkubo T, Yokota T. Can regional spreading of amyotrophic lateral sclerosis motor symptoms be explained by prion-like propagation? J Neurol Neurosurg Psychiatry. 2012 Jul;83(7):739–745.
   PubMed Web of Science ®Google Scholar